Valby, Denmark, December 8, 2020 — H. Lundbeck A/S (Lundbeck) is among the leading companies when it comes to climate action and disclosing efforts according to a new ranking published by the global organization Carbon Disclosure Project (CDP). The ranking acknowledges the actions being made by Lundbeck to reduce CO2-emissions and energy consumption, and positions Lundbeck among the 3 percent best companies globally within climate action and transparency.
CDP is a non-profit organization that runs a global disclosure system for investors, companies, cities, states and regions to manage their environmental impacts. They are known to set the standard for corporate environmental reporting and corporate environmental transparency. More than 9,600 companies participated in this year’s survey.
“We are proud to be ranked among the best companies in the world when it comes to being transparent and taking action on our climate efforts. In Lundbeck, we are ambitious about developing and manufacturing medicines for brain diseases in a responsible and sustainable way. We see this recognition as a proof that we are on the right path,” says Deborah Dunsire, CEO in Lundbeck.
Since 2006, Lundbeck has cut CO2-emissions by 68 percent, equivalent of more than 1,700 households annually. A main part of the reduction comes from optimization of existing buildings, plants, and installations as well as investments in new low-energy machines and plants. Lundbeck has also made a shift from conventional fuel to bio-fuel.
“When we look at reducing CO2-emissions, it is a shared responsibility where we all must take action. At Lundbeck, we have invested in our buildings and machinery to deliver on that responsibility. We are proud to having reduced our emissions by 68 percent since 2006, but we are also ambitious about reducing our CO2-emissions even more in the future,” says Deborah Dunsire, CEO.
Mikkel Ballegaard Pedersen
Media Relations, Corp. Communication
+45 30 83 20 44
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.
Millions of people worldwide live with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.
Our approximately 5,800 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and the US and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 17.0 billion in 2019 (EUR 2.3 billion; USD 2.6 billion).
In the United States, Lundbeck employs more than 1,000 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in a broad range of initiatives each year that support our patient communities. For additional information, visit www.lundbeckus.com and connect on Twitter at @LundbeckUS.